US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,375.27

+19.551.44%

Number of Gainers:17

Number of Losers:2

Number of Flat:1

PE:- -

High:1,386.07

Open:1,359.33

Low:1,359.33

Close:1,355.71

Loading ...

U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors

THOMSON REUTERS

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors

Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress

Simply Wall St.

Pfizer CEO: 'We should not have tariffs' on pharma

BUZZ-Pfizer beats quarterly profit beat, maintains 2025 forecast; shares rise

Abbott Agrees to Integrate Libre Data With Epic's Record System

MT Newswires Live

Pfizer Shares Reverse Course, Last up 4.3%

THOMSON REUTERS

AstraZeneca CEO: Trump tariffs 'not material long term'

Pfizer Shares Rise After Q1 Profit Beats, Reaffirms 2025 Outlook

BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

Pfizer Reports Mixed First Quarter, Affirms Full-Year Outlook

Pfizer CEO Bourla Says Co "Not Going to Be a Strong Top Line Growth Story for Next Three Years, Given Loes, We Expect to Become EPS Growth Story"

THOMSON REUTERS

Pfizer CEO Says Co Has "Ample Room IF There Is a Need to Transfer Production" of Medicines to United States - Conf Call

THOMSON REUTERS

Astrazeneca's Fixed-Duration Calquence-Based Regimen Receives CHMP Recommendation for Leukaemia

MT Newswires Live

Pfizer Eyes Acquisitions After Obesity Drug Setback

AstraZeneca Halts Phase 3 Trial for Prostate Cancer Treatment Combination

MT Newswires Live

Concerns About Tariffs Weigh on Economic Outlook, U.S. Consumer Confidence in April Plunges to Nearly Five-Year Low

Here's Why Astrazeneca (AZN) is a Strong Value Stock

Pfizer Shares Fall 1.8% After Q1 Revenue Miss

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1375.2667,"timestamp":1746215999999,"preClose":1355.7122,"halted":0,"volume":90281388,"delay":0,"changeRate":0.014424,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":19.554565,"latestTime":"05-02 16:00:00 EDT","open":1359.3263,"high":1386.07,"low":1359.3263,"amount":4683518595.783152,"amplitude":0.019727,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.644075,"peRate":21.713814,"turnoverRate":0.005819,"increases":17,"decrements":2,"flats":1,"marketCap":1136531230970,"floatMarketCap":1116501984572.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1386.07,"amplitude":0.019727,"preClose":1355.7122,"low":1359.3263,"pbRate":"3.644075","latestPrice":1375.2667,"volume":90281388,"delay":0,"open":1359.3263,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1341.1263,"twentyDayClose":1401.546,"sixtyDayClose":1373.9138,"secType":"PLATE","market":"US","turnoverRate":0.005819,"peRate":21.713814,"marketCap":1136531230970,"floatMarketCap":1116501984572.5,"timestamp":1746215999999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":17,"down":2,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531764556","title":"U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764556?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU2087621335.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","BK4139","LU0058720904.USD","IE00B19Z3581.USD","LU1585245621.USD","LU1066053197.SGD","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","LU1571399168.USD","LU1430594728.SGD","LU0234570918.USD","IE00B19Z3B42.SGD","BK4566","LU0289739699.SGD","LU1839511570.USD","GILD","BK4583","BK4532","LU1066051498.USD","LU2468319806.SGD","IE00B3T34201.USD","IE0002270589.USD","LU0109394709.USD","LU0889565916.HKD","BK4550","LU0320765992.SGD","BK4578","LU2089984988.USD","BK4568","BK4588"],"gpt_icon":0},{"id":"2531764206","title":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764206","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764206?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:29","pubTimestamp":1745947786,"startTime":"0","endTime":"0","summary":"Gilead Sciences reaches $202 million settlement with US over kickbacks to doctorsNEW YORK, April 29 (Reuters) - Gilead Sciences GILD.O has reached a $202 million settlement to resolve a civil fraud la","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL1N3R7145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4583","LU2468319806.SGD","IE00BSNM7G36.USD","LU1066053197.SGD","IE00B3T34201.USD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1066051498.USD","LU1430594728.SGD","BK4532","BK4139","BK4568","LU0234570918.USD","LU2089984988.USD","IE0002270589.USD","GILD","BK4585","LU0109394709.USD","IE00B19Z3581.USD","BK4578","LU0289739699.SGD","LU1585245621.USD","BK4588","LU1839511570.USD","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","LU1571399168.USD","IE00BZ1G4Q59.USD","LU2087621335.USD","BK4550","LU0320765992.SGD"],"gpt_icon":0},{"id":"2531789793","title":"Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789793","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789793?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:27","pubTimestamp":1745947636,"startTime":"0","endTime":"0","summary":"Gilead Sciences recently announced a presentation at the EASL Congress focusing on liver disease, with promising research in both hepatitis B and C. This comes alongside solid Q1 earnings results where a significant net income turnaround was noted. These developments, combined with a quarterly dividend declaration and ongoing share buybacks, potentially supported a 13% share price increase over the last quarter. Meanwhile, the general market showed strength with a 7% rise, suggesting Gilead's performance aligns with broader positive trends, further buoyed by robust earnings reports across various industries.We've identified 2 possible red flags with Gilead Sciences and understanding the impact should be part of your investment process.NasdaqGS:GILD Revenue & Expenses Breakdown as at Apr 2025. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-nasdaqgs-gild-showcases-172716096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00BKVL7J92.USD","LU1066053197.SGD","LU1066051498.USD","BK4568","BK4566","IE00B3T34201.USD","IE00BSNM7G36.USD","LU2089984988.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","BK4583","LU1839511570.USD","IE0002270589.USD","BK4532","BK4578","IE00B19Z3B42.SGD","LU1430594728.SGD","BK4588","IE00B7SZLL34.SGD","GILD","BK4585","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","LU2087621335.USD","LU1571399168.USD","LU0058720904.USD","LU0289739699.SGD","LU0320765992.SGD","LU1585245621.USD","BK4550","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2531761289","title":"Pfizer CEO: 'We should not have tariffs' on pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2531761289","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531761289?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:16","pubTimestamp":1745947001,"startTime":"0","endTime":"0","summary":"Like his Big Pharma peers, Pfizer  CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on pharmaceutical imports. To be sure, he said Tuesday, the government's national security concerns are \"legitimate.\" But, he added, \"we should not have tariffs.\". \"No country wants to have critical medicines produced ... in countries where tensions are high or can escalate,\" Bourla said on an earnings call. He did not detail what percent of manufacturing is taking place and which components are being produced in the US, but said the company has contingency plans in place.\"If there are tariffs, we have detailed contingency plans that are minimizing the impact. But I'm right now focusing more on the fact that we should not have tariffs,\" Bourla said.CFO David Denton said the company is already expecting a $150 million impact in 2025 from the current slate of tariffs but did not detail which products are impacted.Read more about Pfizer's stock mo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-ceo-we-should-not-have-tariffs-on-pharma-171641146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE000M9KFDE8.USD","BK4533","LU1829250122.USD","LU0320765992.SGD","SG9999003800.SGD","BK4592","LU0289739699.SGD","BK4581","LU0225771236.USD","LU1057294990.SGD","PFE","IE00BLSP4452.SGD","SG9999002232.USD","LU0234572021.USD","LU2417539215.USD","SG9999013999.USD","BK4568","LU0109394709.USD","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","LU0321505439.SGD","BK4007","SGXZ57979304.SGD","LU0058720904.USD","AZN","IE0002270589.USD","LU1883839398.USD","LU0868494617.USD","SG9999002224.SGD","LU0306807586.USD","BK4588","LU1894683264.USD","LU1066053197.SGD","LU0170899867.USD","LU0889565916.HKD","LU0225284248.USD","SG9999011175.SGD","IE00B19Z3581.USD","LU0122379950.USD","BK4534","LU0456855351.SGD","LU0985481810.HKD","BK4585","LU2236285917.USD","LU2462157665.USD","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4550"],"gpt_icon":1},{"id":"2531766423","title":"BUZZ-Pfizer beats quarterly profit beat, maintains 2025 forecast; shares rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2531766423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531766423?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:41","pubTimestamp":1745944907,"startTime":"0","endTime":"0","summary":"BUZZ-Pfizer beats quarterly profit beat, maintains 2025 forecast; shares riseUpdates** Pfizer's PFE.N shares rise 4.4% to $24.06. ** Stock set for its biggest single-day pct. jump in nearly 4 months, if gains hold. ** PFE posts Q1 adj. EPS of $0.92, beating analysts' estimates of $0.67, according to data compiled by LSEG** PFE's Q1 revenue misses estimates due to declining sales of its Paxlovid COVID-19 treatment, but co still sticks by FY revenue forecast of $61 billion-$64 billion** Co says it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations** Including session's moves, PFE has fallen about 10% YTD ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R721V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","BK4533","SG9999003800.SGD","BK4592","LU0289739699.SGD","BK4581","LU0225771236.USD","BK4599","LU1057294990.SGD","PFE","IE00BLSP4452.SGD","LU1894683348.USD","SG9999002232.USD","LU0234572021.USD","SG9999013999.USD","BK4568","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","LU0321505439.SGD","BK4007","SGXZ57979304.SGD","LU0321505868.SGD","LU0058720904.USD","IE0002270589.USD","LU1883839398.USD","LU0868494617.USD","SG9999002224.SGD","LU0306807586.USD","BK4588","LU1894683264.USD","LU1066053197.SGD","LU0170899867.USD","SG9999011175.SGD","LU0225284248.USD","IE00B19Z3581.USD","LU0122379950.USD","BK4534","LU0456855351.SGD","LU0306806265.USD","SG9999001176.SGD","LU0985481810.HKD","BK4585","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4550"],"gpt_icon":1},{"id":"2531766235","title":"Abbott Agrees to Integrate Libre Data With Epic's Record System","url":"https://stock-news.laohu8.com/highlight/detail?id=2531766235","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531766235?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:41","pubTimestamp":1745944871,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (ABT) said Tuesday that it has agreed to integrate data from its Libre continuous glucose monitoring systems into Epic's electronic health record systems in the US under a collabor","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999002232.USD","LU1061106388.HKD","SGXZ23171101.USD","LU0868494617.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","LU1721429741.USD","LU2237957811.SGD","LU0266013472.USD","BK4568","LU0234572021.USD","LU1057294990.SGD","LU2237957902.USD","LU2468319806.SGD","IE00BJT1NW94.SGD","LU2112291526.USD","LU1721429402.USD","ABT","IE0009355771.USD","SG9999002224.SGD","SG9999004303.SGD","BK4082","BK4504","ABT.AU","LU0170899867.USD","LU1989763427.SGD","BK4566","LU0122379950.USD","BK4588","BK4585","IE0002141913.USD","BK4581","BK4533","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU1914381329.SGD","BK4592","LU1989763690.USD","LU2133065610.SGD","LU1691799644.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2531925763","title":"Pfizer Shares Reverse Course, Last up 4.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531925763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531925763?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:13","pubTimestamp":1745943200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R721T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505439.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0058720904.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","SG9999013999.USD","SG9999003800.SGD","LU1894683264.USD","BK4550","LU0289739699.SGD","LU0321505868.SGD","LU0170899867.USD","SG9999002232.USD","BK4581","BK4007","LU0225284248.USD","PFE","LU0234572021.USD","BK4592","BK4534","BK4585","LU0225771236.USD","LU0306807586.USD","LU1883839398.USD","IE0002270589.USD","LU0306806265.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999001176.USD","LU1057294990.SGD","SG9999002224.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","SG9999001176.SGD","BK4599","LU0122379950.USD","IE00BLSP4239.USD","LU0985481810.HKD","BK4568","LU0868494617.USD","LU1066053197.SGD","LU1894683348.USD","LU1066051498.USD","BK4533","BK4588"],"gpt_icon":0},{"id":"2531765500","title":"AstraZeneca CEO: Trump tariffs 'not material long term'","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765500","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765500?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:05","pubTimestamp":1745942725,"startTime":"0","endTime":"0","summary":"AstraZeneca  CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate the industry to reshore manufacturing.\"We believe the best way forward is to not charge tariffs on pharmaceuticals but [instead] create an environment that attracts investments through an attractive corporate tax rate,\" Soriot told Yahoo Finance in an interview Tuesday.He said on an earnings call earlier Tuesday that the company does not view the tariffs as a long-term headwind.Tariffs are \"certainly not material long term,\" Soriot said, adding that AstraZeneca will rely on the existing global network to shift manufacturing as needed.AstraZeneca reported mixed first quarter earnings Tuesday, sending its stock up just under 2% in trading.Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-ceo-trump-tariffs-not-material-long-term-160525760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","LU1829250122.USD","LU2462157665.USD","BK4588","LU2236285917.USD","LU0889565916.HKD","LU0320765992.SGD","LU2417539215.USD","AZN","BK4007","LU2456880835.USD","LU0109394709.USD","BK4585"],"gpt_icon":0},{"id":"2531762025","title":"Pfizer Shares Rise After Q1 Profit Beats, Reaffirms 2025 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2531762025","media":"GuruFocus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531762025?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:01","pubTimestamp":1745942472,"startTime":"0","endTime":"0","summary":"Based on the one year price targets offered by 19 analysts, the average target price for Pfizer is $28.71 with a high estimate of $41.43 and a low estimate of $22.00. The average target implies an upside of 21.18% from the current price of $23.69.Based on GuruFocus estimates, the estimated GF Value for Pfizer Inc in one year is $28.58, suggesting an upside of 20.64% from the current price of $23.69.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2812354/pfizer-shares-rise-after-q1-profit-beats-reaffirms-2025-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["IE000M9KFDE8.USD","BK4533","SG9999003800.SGD","BK4592","LU0289739699.SGD","BK4581","LU0225771236.USD","BK4599","LU1057294990.SGD","PFE","IE00BLSP4452.SGD","LU1894683348.USD","SG9999002232.USD","LU0234572021.USD","SG9999013999.USD","BK4568","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","LU0321505439.SGD","BK4007","SGXZ57979304.SGD","LU0321505868.SGD","LU0058720904.USD","IE0002270589.USD","LU1883839398.USD","LU0868494617.USD","SG9999002224.SGD","LU0306807586.USD","BK4588","LU1894683264.USD","LU1066053197.SGD","LU0170899867.USD","SG9999011175.SGD","LU0225284248.USD","IE00B19Z3581.USD","LU0122379950.USD","BK4534","LU0456855351.SGD","LU0306806265.USD","SG9999001176.SGD","LU0985481810.HKD","BK4585","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4550"],"gpt_icon":1},{"id":"2531765684","title":"BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765684","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765684?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:39","pubTimestamp":1745941187,"startTime":"0","endTime":"0","summary":"We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where BridgeBio Pharma, Inc.  stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential.Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson’s Tiger Management. Robertson put together a formidable team of young traders – called the Tiger Cubs – in the 1990s, and most founded their own hedge funds after exit. Some other noteworthy names include Robert Citrone, Chase Coleman, and John Griffin. Halvorsen is the wealthiest Tiger Cub. Forbes Magazine ranks him at position 382 in the Richest People in the World in 2025 list with an $8 billion net worth.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bridgebio-pharma-inc-bbio-among-153947548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BNTX","BK4139","BK4505","PSQ","MNQmain","SQQQ","QLD","BK4548","BK4585","TSYW.SI","BK4551","BK4588","USJW.SI","NVIW.SI","NQmain","USAW.SI","BK4535",".IXIC","QID","BBIO","TQQQ","BK4568"],"gpt_icon":1},{"id":"2531676866","title":"BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2531676866","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531676866?lang=en_us&edition=fundamental","pubTime":"2025-04-29 23:38","pubTimestamp":1745941137,"startTime":"0","endTime":"0","summary":"We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc.  stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential.Ole Andreas Halvorsen is one of the prominent names among former employees of Julian Robertson’s Tiger Management. Robertson put together a formidable team of young traders – called the Tiger Cubs – in the 1990s, and most founded their own hedge funds after exit. Some other noteworthy names include Robert Citrone, Chase Coleman, and John Griffin. Halvorsen is the wealthiest Tiger Cub. Forbes Magazine ranks him at position 382 in the Richest People in the World in 2025 list with an $8 billion net worth.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biomarin-pharmaceutical-inc-bmrn-among-153857768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","USAW.SI","USJW.SI","BK4585","BNTX","TSYW.SI","BK4139","BK4551","BK4548",".IXIC","BMRN","IE00B19Z3B42.SGD","SQQQ","QID","QLD","IE0002270589.USD","BK4568","IE00B19Z3581.USD","BK4535","PSQ","MNQmain","TQQQ","IE00B7SZLL34.SGD","NVIW.SI","NQmain","BK4588"],"gpt_icon":1},{"id":"2531752767","title":"Pfizer Reports Mixed First Quarter, Affirms Full-Year Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2531752767","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531752767?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:47","pubTimestamp":1745938030,"startTime":"0","endTime":"0","summary":"Pfizer's  first-quarter earnings unexpectedly increased year on year even as sales fell below Wall Street's estimates, while the pharmaceutical giant reiterated its full-year outlook.Adjusted per-share earnings rose to $0.92 from $0.82 a year earlier and surpassed the consensus on FactSet of $0.67. Revenue fell 8% to $13.72 billion, below analysts' $13.92 billion estimate.For 2025, the company continues to expect adjusted EPS guidance of $2.80 to $3 and revenue of $61 billion to $64 billion. Analysts are looking for non-GAAP EPS of $2.94 on revenue of $62.75 billion. In the previous year, adjusted EPS surged 69% to $3.11, while sales rose 7% to $63.63 billion.\"In addition, we have identified additional opportunities to drive improvements in productivity and operational efficiency in our  organization through enhanced digital enablement and automation,\" according to the CFO. \"We expect approximately $500 million in savings associated with these efforts to be realized by the end of 2026 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-reports-mixed-first-quarter-144710844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","LU0225284248.USD","LU0456855351.SGD","LU0306806265.USD","SG9999011175.SGD","IE00BBT3K403.USD","SG9999013999.USD","SGXZ57979304.SGD","SG9999003800.SGD","LU1883839398.USD","LU1894683264.USD","LU0289739699.SGD","LU0234572021.USD","BK4568","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4588","LU1023059063.AUD","PFE","BK4592","SG9999001176.SGD","LU0321505439.SGD","BK4585","LU1894683348.USD","LU0170899867.USD","BK4599","IE0002270589.USD","BK4533","LU0122379950.USD","IE00B19Z3B42.SGD","SG9999001176.USD","SG9999002224.SGD","LU1057294990.SGD","LU0058720904.USD","BK4534","LU0225771236.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU1066053197.SGD","BK4007","IE00BLSP4452.SGD","LU0868494617.USD","LU1066051498.USD","LU0985481810.HKD","LU0321505868.SGD","BK4581"],"gpt_icon":1},{"id":"2531751132","title":"Pfizer CEO Bourla Says Co \"Not Going to Be a Strong Top Line Growth Story for Next Three Years, Given Loes, We Expect to Become EPS Growth Story\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2531751132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531751132?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:42","pubTimestamp":1745937769,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R726B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999013999.USD","LU1894683264.USD","LU0225771236.USD","LU0321505868.SGD","IE0002270589.USD","BK4581","PFE","LU0058720904.USD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","BK4592","SG9999002224.SGD","SG9999002232.USD","LU0289739699.SGD","LU1023059063.AUD","LU1883839398.USD","IE00BLSP4239.USD","BK4568","LU0306806265.USD","LU1066051498.USD","SG9999003800.SGD","SG9999001176.SGD","LU0225284248.USD","LU0122379950.USD","BK4550","LU1057294990.SGD","LU0868494617.USD","BK4534","IE00B19Z3581.USD","LU1894683348.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","BK4585","LU0321505439.SGD","LU0234572021.USD","SG9999011175.SGD","BK4533","BK4007","BK4599","BK4588","LU0306807586.USD","IE00BBT3K403.USD","SG9999001176.USD","LU1066053197.SGD","LU0985481810.HKD","LU0170899867.USD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2531594047","title":"Pfizer CEO Says Co Has \"Ample Room IF There Is a Need to Transfer Production\" of Medicines to United States - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2531594047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531594047?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:42","pubTimestamp":1745937769,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R726B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505868.SGD","IE00B19Z3B42.SGD","BK4550","BK4581","LU0225771236.USD","LU0225284248.USD","BK4568","LU0058720904.USD","LU0170899867.USD","SGXZ57979304.SGD","BK4599","LU1057294990.SGD","IE00B19Z3581.USD","LU0321505439.SGD","LU1066053197.SGD","LU0306807586.USD","IE000M9KFDE8.USD","LU1883839398.USD","LU1894683264.USD","LU0456855351.SGD","SG9999002232.USD","BK4585","LU1894683348.USD","SG9999003800.SGD","SG9999001176.SGD","LU0985481810.HKD","LU0289739699.SGD","BK4534","BK4592","PFE","SG9999002224.SGD","LU0868494617.USD","BK4533","SG9999001176.USD","LU0306806265.USD","IE0002270589.USD","IE00BLSP4452.SGD","BK4007","BK4588","SG9999011175.SGD","LU0234572021.USD","IE00BBT3K403.USD","LU0122379950.USD","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","SG9999013999.USD"],"gpt_icon":0},{"id":"2531759246","title":"Astrazeneca's Fixed-Duration Calquence-Based Regimen Receives CHMP Recommendation for Leukaemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2531759246","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531759246?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:41","pubTimestamp":1745937700,"startTime":"0","endTime":"0","summary":"Astrazeneca  said Tuesday its Calquence fixed-duration regimen was recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use to treat adults with previously untreated chronic lymphocytic leukaemia.CHMP's positive opinion was based on a phase 3 trial that indicated that Calquence combinations with venetoclax and obinutuzumab showed improved progression-free survival compared with chemoimmunotherapy, according to a statement.Shares were up 0.6% in recent trading.Price: 70.38, Change: +0.45, Percent Change: +0.64","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2456880835.USD","BK4007","LU0320765992.SGD","LU1829250122.USD","LU2236285917.USD","BK4087","BK4585","BK4568","CHMP","LU0109394709.USD","LU2417539215.USD","LU2462157665.USD","BK4588","AZN","LU0889565916.HKD"],"gpt_icon":0},{"id":"2531751895","title":"Pfizer Eyes Acquisitions After Obesity Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2531751895","media":"GuruFocus.com","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531751895?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:32","pubTimestamp":1745937141,"startTime":"0","endTime":"0","summary":"Pfizer  is overhauling its cardiometabolic pipeline and weighing acquisitions after an oral weight-loss candidate stumbled, even as its Q1 results delivered a mixed bag of beats and misses.GuruFocus has detected 6 Warning Signs with PFE.The New Yorkbased drugmaker reported $13.7 billion in first-quarter revenue, roughly $400 million shy of analysts' $14.09 billion consensus, but topped bottom-line forecasts and confirmed its 2025 earnings outlook.Revenue slid about 8% year-over-year, driven largely by a steep drop in Paxlovid sales to $491 million versus a $902 million forecast. That decline was only partly offset by Comirnaty, Pfizer's COVID vaccine co-developed with BioNTech, which generated $565 million and outpaced the $325.5 million estimate.He added that Pfizer would build our cardiometabolic pipeline, including in obesity, by advancing internal programs such as our GIPR antagonist and pursuing external opportunities that could include partnerships or acquisitions. That strategic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-eyes-acquisitions-obesity-drug-143221205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","LU0321505439.SGD","SG9999001176.USD","IE00BBT3K403.USD","LU0289739699.SGD","IE00B19Z3581.USD","LU0122379950.USD","BK4592","LU1894683264.USD","LU0321505868.SGD","BK4533","BK4588","LU0225771236.USD","SG9999013999.USD","PFE","SG9999002224.SGD","LU0456855351.SGD","LU1066053197.SGD","LU0306806265.USD","SG9999003800.SGD","LU0170899867.USD","BK4581","LU1894683348.USD","LU1883839398.USD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","BK4585","SGXZ57979304.SGD","LU1066051498.USD","BK4007","LU0225284248.USD","IE00BLSP4239.USD","LU0058720904.USD","IE0002270589.USD","BK4599","LU0868494617.USD","LU1057294990.SGD","LU0306807586.USD","LU1023059063.AUD","SG9999001176.SGD","LU0234572021.USD","SG9999002232.USD","BK4534","LU0985481810.HKD","IE000M9KFDE8.USD","BK4550"],"gpt_icon":1},{"id":"2531756700","title":"AstraZeneca Halts Phase 3 Trial for Prostate Cancer Treatment Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2531756700","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531756700?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:27","pubTimestamp":1745936862,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) halted its phase 3 trial for prostate cancer treatment Truqap based on the recommendation of an independent data monitoring committee.The trial, which evaluated the efficacy and safe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU0889565916.HKD","BK4568","AZN","LU2417539215.USD","LU2456880835.USD","LU2462157665.USD","LU2236285917.USD","LU0320765992.SGD","BK4007","LU1829250122.USD","BK4588","LU0109394709.USD"],"gpt_icon":0},{"id":"2531475165","title":"Concerns About Tariffs Weigh on Economic Outlook, U.S. Consumer Confidence in April Plunges to Nearly Five-Year Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2531475165","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531475165?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:25","pubTimestamp":1745936700,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 29th: The U.S. Consumer Confidence Index fell to nearly a 5-year low in April, as concerns over tariffs escalated, dragging down economic prospects. Data from the U.S. Conference Board shows that the April Consumer Confidence Index dropped by 7.9 points to 86.0, the lowest level since May 2020. Stephanie Guichard, Chief Economist of the World Business Federation Global Index, stated: \"Consumer confidence in April declined for the fifth consecutive month, reaching its lowest level since the outbreak of the COVID-19 pandemic.\" It is expected that tomorrow's U.S. GDP data will show a significant slowdown in economic growth in the first quarter, as businesses rushed to import goods to avoid the cost increase due to tariffs, leading to a surge in imports. Consumer spending may also slow significantly, as persistently high inflation and concerns about the economic impact of tariffs will prompt some households to cut back on spending to increase savings. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/291753","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4585","BK4139","BK4588","BNTX","BK4551","BK4535","BK4568","BK4548"],"gpt_icon":0},{"id":"2531765632","title":"Here's Why Astrazeneca (AZN) is a Strong Value Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2531765632","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531765632?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:40","pubTimestamp":1745934006,"startTime":"0","endTime":"0","summary":"Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.Why Investors Should Pay Attention to This Value Stock. Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.Many value investors pay close attention to a company's earnings as well. For AZN, two analysts revised their earnings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-astrazeneca-azn-strong-134006344.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4007","LU0109394709.USD","LU0320765992.SGD","LU2456880835.USD","BK4588","LU0889565916.HKD","LU1829250122.USD","LU2236285917.USD","BK4568","LU2417539215.USD","LU2462157665.USD","AZN"],"gpt_icon":0},{"id":"2531342737","title":"Pfizer Shares Fall 1.8% After Q1 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2531342737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531342737?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:32","pubTimestamp":1745933557,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R71QW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4592","IE00BBT3K403.USD","LU0170899867.USD","LU0058720904.USD","BK4588","LU0868494617.USD","LU0306806265.USD","BK4581","BK4568","LU1894683264.USD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4599","LU0321505868.SGD","IE00B19Z3581.USD","LU0289739699.SGD","LU0225284248.USD","IE00BLSP4452.SGD","SG9999002224.SGD","BK4533","LU0306807586.USD","BK4585","IE00BLSP4239.USD","LU1883839398.USD","LU1057294990.SGD","LU0234572021.USD","LU0985481810.HKD","LU1066053197.SGD","LU1023059063.AUD","SG9999003800.SGD","SG9999011175.SGD","IE000M9KFDE8.USD","IE0002270589.USD","SG9999013999.USD","BK4534","SG9999002232.USD","LU0321505439.SGD","BK4007","LU0225771236.USD","PFE","SG9999001176.USD","LU0456855351.SGD","SG9999001176.SGD","BK4550","SGXZ57979304.SGD","LU1894683348.USD","LU1066051498.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":6,"totalSize":343,"code":"91000000","status":"200"}]}}